Comparing two imaging methods for diagnosing pulmonary fibrosis
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
PHASE1 · Peking Union Medical College Hospital · NCT05121779
This study is testing if a new imaging method called 68Ga-FAPI PET/CT can better diagnose and monitor treatment for people with pulmonary fibrosis compared to the standard method, 18F-FDG PET/CT.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05121779 on ClinicalTrials.gov |
What this trial studies
This study investigates the diagnostic value of 68Ga-FAPI PET/CT compared to 18F-FDG PET/CT in patients with pulmonary fibrosis. It aims to determine if 68Ga-FAPI, which targets activated fibroblasts, is more effective in assessing the severity of the disease and monitoring therapy response. The study will involve patients who have suspected or confirmed pulmonary fibrosis and will require their consent to participate. By conducting a head-to-head comparison, the research seeks to provide insights into the most effective imaging modality for this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with suspected or confirmed pulmonary fibrosis.
Not a fit: Patients who are pregnant, breastfeeding, or have known allergies to FAPI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment monitoring for patients with pulmonary fibrosis.
How similar studies have performed: Preliminary research suggests that FAPI-PET/CT imaging may be more sensitive than FDG-PET/CT for certain inflammatory conditions, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * suspected or confirmed pulmonary fibrosis patients; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * known allergy against FAPI * any medical condition that in the opinion of the investigator may significantly interfere with study compliance
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Zhaohui Zhu, MD — Peking Union Medical College Hospital
- Study coordinator: Zhaohui Zhu, MD
- Email: 13611093752@163.com
- Phone: 86-13611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pulmonary Fibrosis